Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
Authors
Keywords
-
Journal
Blood Advances
Volume 5, Issue 13, Pages 2707-2716
Publisher
American Society of Hematology
Online
2021-07-01
DOI
10.1182/bloodadvances.2020004155
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines
- (2020) Stephen J Schuster et al. BLOOD
- Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
- (2020) Loretta J. Nastoupil et al. JOURNAL OF CLINICAL ONCOLOGY
- Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity
- (2020) Caron A. Jacobson et al. JOURNAL OF CLINICAL ONCOLOGY
- Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels
- (2020) Tobias Roider et al. NATURE CELL BIOLOGY
- Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data
- (2020) Yazeed Sawalha et al. OncoTargets and Therapy
- High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma
- (2020) Erin A. Dean et al. Blood Advances
- Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
- (2020) Chelsea C. Pinnix et al. Blood Advances
- Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
- (2020) Frederick L. Locke et al. Blood Advances
- CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison
- (2020) Peter Dreger et al. Blood Advances
- Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
- (2019) Franck Morschhauser et al. Lancet Haematology
- Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
- (2019) E. González-Barca et al. BONE MARROW TRANSPLANTATION
- POLARGO: A Randomized Phase III Study Evaluating Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Who Had Received One or More Previous Therapies
- (2019) Andrew K McMillan et al. BLOOD
- Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2019) Laurie H. Sehn et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety
- (2018) Wolfgang Hiddemann et al. JOURNAL OF CLINICAL ONCOLOGY
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation
- (2017) Alex F. Herrera et al. JOURNAL OF CLINICAL ONCOLOGY
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
- (2015) E Van Den Neste et al. BONE MARROW TRANSPLANTATION
- Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
- (2015) Maria Corinna A Palanca-Wessels et al. LANCET ONCOLOGY
- High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma
- (2015) T Aoki et al. Blood Cancer Journal
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started